trending Market Intelligence /marketintelligence/en/news-insights/trending/bcKvReE-t3SisMuT-I4Myg2 content esgSubNav
In This List

Adaptimmune, Bellicum to collaborate on T-cell therapies

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Adaptimmune, Bellicum to collaborate on T-cell therapies

Adaptimmune Therapeutics PLC and Bellicum Pharmaceuticals Inc. signed a deal to collaborate on the evaluation, development and commercialization of next-generation T-cell therapies.

The companies said they agreed to utilize Adaptimmune's affinity-optimized SPEAR T-cells to evaluate Bellicum's GoTCR technology for the potential to create enhanced T-cell receptor product candidates. Based on the results of the pre-clinical proof-of-concept phase, the companies will move to a two-target co-development and co-commercialization phase.